<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27443" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Intermittent Porphyria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gonzalez-Mosquera</surname>
            <given-names>Luis F.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sonthalia</surname>
            <given-names>Sidharth</given-names>
          </name>
          <aff>SKINNOCENCE: The Skin Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Luis Gonzalez-Mosquera declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27443.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute intermittent porphyria is a rare autosomal dominant disease characterized by a deficiency of hydroxymethylbilane synthase (HMBS). It presents with abdominal pain, nausea, vomiting, peripheral neuropathy, and seizures. Treatment for acute attacks is intravenous heme. Definitive treatment is an orthotopic liver transplant. This activity gives an overview of the etiology, clinical presentation, evaluation, management, and treatment of the disease by an interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of acute intermittent porphyria.</p></list-item><list-item><p>Review the evaluation of acute intermittent porphyria.</p></list-item><list-item><p>Outline the management approaches and therapeutic options available for acute intermittent porphyria.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance early diagnosis and management of acute intermittent porphyria and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27443&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27443">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27443.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>'Porphyria' has been derived from the ancient Greek word porphura, meaning purple. Porphyrins are precursors of heme, an essential component of hemoglobin. Each subunit of hemoglobin is a globular protein containing an embedded heme group that contains one iron atom, capable of binding one oxygen molecule. The heme synthesis pathway is a multi-step process that involves a specific enzyme at every step. Thus, porphyrias are distinct clinical syndromes, which arise due to deficiency or defect in a particular enzyme needed for a specific step of the heme synthesis pathway. Although these syndromes have conventionally been classified depending on the predominant system involved (cutaneous vs. neurohepatic), significant overlap occurs, and many porphyrias present with mixed symptoms.</p>
        <p>The clinical presentation, severity, and prognosis of individual porphyrias depend on which enzyme is deficient and the corresponding heme precursor or porphyrin accumulation. Acute intermittent porphyria (AIP) ranks as the most common and severe form of acute porphyria. Other acute porphyrias include hereditary coproporphyria (HCP), variegate porphyria (VP), and 5-aminolevulinic acid (ALA) dehydratase deficiency porphyria&#x000a0;(Doss porphyria).<xref ref-type="bibr" rid="article-27443.r1">[1]</xref></p>
        <p>Similar to the majority of porphyrias, AIP shows an autosomal dominant pattern of inheritance. Acute porphyrias like AIP characteristically demonstrate acute episodes of neurovisceral symptoms but may not manifest fully for a long time. AIP manifests as episodes of abdominal pain, neuropathies, and constipation, but, unlike most other porphyrias, patients with AIP do not develop a cutaneous rash. The primary enzymatic defect in AIP is the deficiency of porphobilinogen-deaminase, also called hydroxymethylbilane synthase (HMBS), the third enzyme in heme synthesis. The acute attacks of AIP are a result of the uncontrolled upregulation of the ALA synthase enzyme. The diagnosis of AIP gets delayed due to nonspecific symptoms and similarities with other diseases. The only cure is orthoptic liver transplantation.<xref ref-type="bibr" rid="article-27443.r2">[2]</xref><xref ref-type="bibr" rid="article-27443.r3">[3]</xref></p>
      </sec>
      <sec id="article-27443.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Acute intermittent porphyria results from mutations in the HMBS gene, which causes about 50% of HMBS deficiency. The gene is on the 11q24.1-q24.2 chromosome. For now, there are known 391 HMBS gene mutations.<xref ref-type="bibr" rid="article-27443.r4">[4]</xref>&#x000a0;This deficiency is noticeable in the acute attacks, where the heme pool in the liver gets used, and there is the induction of delta-aminolevulinic acid synthase (ALAS1). This process leads to delta-aminolevulinic (ALA) accumulation and porphobilinogen (PBG), which are the immediate precursors proximal to the HMBS.<xref ref-type="bibr" rid="article-27443.r3">[3]</xref>&#x000a0;</p>
        <p>Inducers of acute attacks are alcohol, infections, low caloric intake, reproductive hormones change, and high-risk porphyrogenic drugs. The Norwegian Porphyria Centre (NAPOS), with the European Porphyria Network (Epnet), has created a list of medications that clinicians must avoid using in porphyria patients. These drugs include ketamine, thiopental, chloramphenicol, erythromycin, nitrofurantoin, rifampicin, trimethoprim/sulfamethoxazole, spironolactone, methyldopa, valproic acid, carbamazepine, phenytoin, phenobarbital, primidone, and risperidone.<xref ref-type="bibr" rid="article-27443.r5">[5]</xref></p>
      </sec>
      <sec id="article-27443.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Estimates of the combined prevalence of acute porphyrias are 5 cases per 10000 persons. Out of all these clinical syndromes, porphyria cutanea tarda (PCT) that has prominent cutaneous features, is the most common porphyria, with an estimated prevalence of 1 in 10000. AIP, the most common acute porphyria, has an overall European prevalence of approximately 1 in 2000,&#x000a0;with a higher incidence of 1 in 1000 in Sweden due to the founder effect. Recently, there are also reports of the founder effect correlating with a higher prevalence of AIP in certain ethnic groups in Argentina and Spain.<xref ref-type="bibr" rid="article-27443.r6">[6]</xref><xref ref-type="bibr" rid="article-27443.r7">[7]</xref></p>
        <p>Acute intermittent porphyria is a low-penetrant genetic metabolic disease with penetrance considered to be around 10% to 20%.<xref ref-type="bibr" rid="article-27443.r8">[8]</xref> Excepting specific AIP populations, the penetrance of AIP in the general population has been estimated to be less than 1%.<xref ref-type="bibr" rid="article-27443.r9">[9]</xref> Manifest AIP (MAIP) is considered when carriers develop typical acute neurovisceral attacks with an elevation of porphyrin precursors. In the absence of clinical episodes, it is referred to as latent AIP (LAIP). Although higher penetrance has links to specific mutations, the overall genetic susceptibility factors underlying penetrance remain unknown.</p>
        <p>Acute intermittent porphyria affects women to a greater degree than men, with a ratio of between 1.5 and 2 to 1. Attacks are rare before puberty. The typical age for the appearance of symptoms is between 18 to 40 years.</p>
      </sec>
      <sec id="article-27443.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Acute attacks of acute intermittent porphyria are more frequent in women, especially in the post-pubertal age group. The acute attacks of AIP are typically triggered by certain factors, which include several drugs, infection, fasting, alcohol, steroid hormones, as stated above.</p>
        <p>In acute intermittent porphyria, the neurologic damage occurs due to the accumulation of the porphyrin precursors, porphobilinogen, and aminolevulinic acid (ALA). The AIP-associated neurological damage manifests as peripheral and autonomic neuropathies and psychiatric manifestations.</p>
        <p>The exact mechanism by which elevated levels of porphobilinogen and ALA lead to symptomatic disease remains enigmatic because most patients with the genetic defect do not present with symptoms despite excessive porphyrin secretion.</p>
        <p>A recent (2017) case-control study in 50 patients reported the association of acute intermittent porphyria with systemic inflammation. Storjord et al. found that the levels of insulin, C-peptide, prealbumin, and markers of kidney function, were decreased in symptomatic patients only, sparing the asymptomatic ones. They postulated that in symptomatic patients of AIP, reduced insulin release is associated with enhanced disease activity and compromised kidney function.<xref ref-type="bibr" rid="article-27443.r10">[10]</xref></p>
      </sec>
      <sec id="article-27443.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acute attacks of acute intermittent porphyria usually last for up to a week.&#x000a0;</p>
        <p>The symptoms progress as follows:<xref ref-type="bibr" rid="article-27443.r6">[6]</xref>&#x000a0;Abdominal pain, then psychiatric symptoms, and finally peripheral neuropathies.&#x000a0;</p>
        <p>The<bold> abdominal pain</bold> is typically severe, epigastric, and colicky. It tends to last for several days.&#x000a0;It can be associated with constipation and vomiting.<xref ref-type="bibr" rid="article-27443.r11">[11]</xref></p>
        <p>Patients can present with a broad spectrum of <bold>psychiatric symptoms, </bold>such as depression<bold>,</bold>&#x000a0;which are accompanied by concurrent abdominal and/or neurologic symptoms. A study conducted in Sweden demonstrated an increased risk of schizophrenia or bipolar disorder in patients with AIP, as well as in their relatives. <xref ref-type="bibr" rid="article-27443.r12">[12]</xref></p>
        <p><bold>Peripheral</bold>
<bold>neuropathies</bold>&#x000a0;can manifest as a weakness that&#x000a0;begins in the lower extremities and ascends, although any nerve distribution may be affected. This presentation can mimic Guillain-Barre syndrome (GBS). Hypertension and tachycardia secondary to autonomic neuropathies can also occur.</p>
        <p><bold>Central nervous system</bold> signs may include delirium, weakness with progression to quadriplegia and respiratory failure,&#x000a0;cortical blindness, and even coma. In&#x000a0;5% of cases, patients can develop seizures, with partial seizures being the most common subtype.<xref ref-type="bibr" rid="article-27443.r13">[13]</xref> Sometimes red or brown urine may be observed, which darkens on exposure to air, light, and warmth. It is important to note that, unlike porphyria cutanea tarda, AIP does not have any cutaneous manifestations.</p>
        <p>In conventional terms, patients have been reported to be completely free of symptoms in between the attacks. However, it is also suggested that 20% to 64% of patients may suffer from disabling chronic manifestations such as pain, nausea, fatigue, and neuropathic features, including numbness and tingling sensations.<xref ref-type="bibr" rid="article-27443.r14">[14]</xref></p>
      </sec>
      <sec id="article-27443.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of acute intermittent porphyria results from finding elevated PBG in urine in a random sample kept protected from light. Diagnostic confirmation should include quantitative measurement of PBG, ALA, and total porphyrins from the same urine sample. Normal values are 0 to 4 mg/L, but values may reach as high as 25 to 100 mg of ALA and 50 to 200 mg of PBG during an acute attack of AIP.</p>
        <p>A urinary PBG level of only 0 to 4 mg/L during acute symptoms almost rules out acute porphyria as the cause of neurovisceral symptoms.</p>
        <p>Although urine collection for quantification of PBG and ALA is optimal during the peak of an attack of AIP, it may be collected within a few days to weeks after the acute episode also, owing to the persistent elevation of urinary ALA and PBG for many months to years after an attack.<xref ref-type="bibr" rid="article-27443.r15">[15]</xref> The only exception to this leniency is the timed collection of urine, which arises if the&#x000a0;patient has received treatment with a 4- to 5-day course of intravenous heme.<xref ref-type="bibr" rid="article-27443.r1">[1]</xref></p>
        <p>Elevation of urine porphyrins, especially copro porphobilinogen (caused by spontaneous polymerization of porphobilinogen in the urine), is often observable. However, it merits noting that the nonspecific elevation of urine porphyrins, especially coproporphyrins (1 to 2 times&#x000a0;the reference range), is common and not specific for porphyria. Stool porphyrins are typically within the reference range or just mildly elevated.</p>
        <p>An increase in plasma porphyrin confirmed by increased fluorescence emission scan peak at 619 nm can present. Molecular and DNA testing of HMBS deficiency is unnecessary for the diagnosis but has utility for family screening.<xref ref-type="bibr" rid="article-27443.r16">[16]</xref><xref ref-type="bibr" rid="article-27443.r11">[11]</xref><xref ref-type="bibr" rid="article-27443.r17">[17]</xref></p>
        <p>
<bold>Associated Laboratory Abnormalities (During An Acute Attack):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyponatremia - most common</p>
          </list-item>
          <list-item>
            <p>Hypomagnesemia is also common</p>
          </list-item>
          <list-item>
            <p>Mild aminotransferase elevations&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mild leucocytosis</p>
          </list-item>
        </list>
        <p>
<bold>Differentiating Between Acute Porphyrias</bold>
</p>
        <p>As mentioned below (vide infra), most acute porphyrias' symptomatology shows significant overlap. Symptoms of AIP are&#x000a0;often clinically indistinguishable from those of hereditary coproporphyria and variegate porphyria. Although the diagnostic approach to distinguish AIP from other acute porphyrias has little evidence backing at present, new evidence-based diagnostic strategies are under development for these conditions.&#x000a0;</p>
        <p>
<bold>Plasma Fluorescence Staining</bold>
</p>
        <p>In contrast to AIP, HCP, and other porphyrias in which the sera of subjects with biochemically active disease have emission peaks at approximately 619 nm to 620 nm,&#x000a0;the serum from patients with VP&#x000a0;have a unique porphyrin-peptide in plasma that has its peak fluorescence at approximately 626 nm, following excitation by light of 410 nm (the Soret band). This reaction forms the basis of the utility of fluorescence of diluted sera at physiologic pH to differentiate VP from other acute as well as cutaneous porphyrias.<xref ref-type="bibr" rid="article-27443.r18">[18]</xref></p>
        <p>
<bold>Emerging Role of Genetic Mutation Analysis in Diagnostic Confirmation&#x000a0;</bold>
</p>
        <p>The specific type of acute porphyria is now discernable by genetic testing, which is available commercially at several labs. The approach involves sequencing of the four genes that are defective in the acute porphyrias:<xref ref-type="bibr" rid="article-27443.r1">[1]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Gene/Type of Acute Porphyria</bold> &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">ALAD/</italic>ALAD-deficient porphyria (Doss porphyria) &#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">HMBS/</italic>AIP &#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">CPOX/</italic>HCP &#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">PPOX/</italic>VP &#x000a0;</p>
          </list-item>
        </list>
        <p>The evolution of&#x000a0;next-generation sequencing&#x000a0;(NGS) to porphyria diagnosis is ongoing, with investigators having recently designed a panel containing four genes -&#x000a0;<italic toggle="yes">ALAS1, HMBS</italic>,&#x000a0;<italic toggle="yes">CPOX,</italic>&#x000a0;and&#x000a0;<italic toggle="yes">PPOX</italic>&#x000a0;for&#x000a0;mutational&#x000a0;analysis&#x000a0;of AIP, HCP, and VP.<xref ref-type="bibr" rid="article-27443.r19">[19]</xref></p>
      </sec>
      <sec id="article-27443.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Initial And Symptom-Oriented Treatment</bold>
</p>
        <p>Owing to the simulation of symptoms of acute intermittent porphyria by several abdominal, metabolic, and neuropsychiatric conditions, establishing a confirmed diagnosis forms the core of the management of AIP.</p>
        <p>Avoidance of precipitants, especially drugs, requires extreme emphasis, ingraining it in the patient and relatives' psyche. (<italic toggle="yes">vide infra</italic>)</p>
        <p>When a patient with confirmed AIP presents with an acute attack, the usual first approach is to load the patient with a high carbohydrate diet or intravenously administered dextrose&#x000a0;to inhibit hepatic ALAS1 transcription. Administration of&#x000a0;10% dextrose in 0.45% saline should start immediately.&#x000a0;If the patient does not present with weakness, vomiting, or hyponatremia, a trial of a high carbohydrate diet for 48 hours before starting specific treatment is the current recommendation.<xref ref-type="bibr" rid="article-27443.r20">[20]</xref><xref ref-type="bibr" rid="article-27443.r13">[13]</xref><xref ref-type="bibr" rid="article-27443.r11">[11]</xref>&#x000a0;</p>
        <p>For pain, parenteral opiates are the best option (morphine, diamorphine, and fentanyl). Nausea and vomiting are controllable with prochlorperazine, promazine, and ondansetron.&#x000a0; These symptoms usually start abating in 72 to 96&#x000a0; hours.<xref ref-type="bibr" rid="article-27443.r20">[20]</xref> For tachycardia and hypertension, preferred medications are beta-blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers (diltiazem). If the patient presents with seizures, they are controllable with diazepam, magnesium sulfate, or clonazepam.<xref ref-type="bibr" rid="article-27443.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Specific Treatment</bold>
</p>
        <p>Intravenous administration of heme is the specific therapy. It replenishes the hepatocyte heme pool and down-regulates ALAS1, resulting in reduced production of porphyrin precursors and corresponding improvement in symptoms.<xref ref-type="bibr" rid="article-27443.r21">[21]</xref>&#x000a0;Heme not only controls hepatic ALAS1 by down-regulating ALAS1 transcription but also by inducing mRNA destabilization or by blocking the mitochondrial import of the mature enzyme.<xref ref-type="bibr" rid="article-27443.r3">[3]</xref></p>
        <p>Owing to the delayed effect of heme therapy on reducing plasma ALA and PBG levels, intravenous heme therapy (IHT) should be&#x000a0;administered without delay in severe acute attacks and maintained for four days (3 to 4 mg/kg of heme/day). A response usually appears on the third day with a decrease of urine and serum PBG. Panhematin administration should be through a large peripheral vein or central line due to the risk of phlebitis in small veins, a risk also reduced by preparing it with human albumin instead of water. Other complications are an increase in prothrombin time during the first 2 hours and increased iron production in the liver. Patient discharge can take place when parenteral opioids can stop, and they can tolerate oral drugs.<xref ref-type="bibr" rid="article-27443.r20">[20]</xref></p>
        <p>Excepting occasional complaints of headache or pyrexia, IHT is well tolerated. However, there are inherent risks associated with recurrent treatments with IHT, of which every caregiver should be cognizant.</p>
        <p>
<bold>Risks Associated With Recurrent IHT</bold>
</p>
        <p>The following enumerates the significant issues associated with recurrent IHT - the&#x000a0;need to replace the venous access to prevent thromboembolic disease, risk of liver fibrosis,&#x000a0;hepatic iron overload,&#x000a0;and development of therapeutic 'tolerance' to heme infusion. Research has shown that heme infusion can induce the expression of hepatic heme oxygenase 1 (HMOX1, EC 1.14.99.3, HGNC: 5013).<xref ref-type="bibr" rid="article-27443.r22">[22]</xref><xref ref-type="bibr" rid="article-27443.r23">[23]</xref><xref ref-type="bibr" rid="article-27443.r24">[24]</xref> HMOX1 is&#x000a0;the crucial enzyme of heme catabolism. Its induction by heme therapy results in the reduction of hepatocyte heme pool and consequently enhanced expression of ALAS1.<xref ref-type="bibr" rid="article-27443.r25">[25]</xref> This heme-induced auto-catabolic effect generates the tolerance reported in some patients.</p>
        <p>Currently,&#x000a0;the only established cure for acute intermittent porphyria is orthotopic liver transplantation (OLT) with a reported survival rate of around 80%.<xref ref-type="bibr" rid="article-27443.r26">[26]</xref><xref ref-type="bibr" rid="article-27443.r27">[27]</xref> However, a high risk (40%) of hepatic artery thrombosis with OLT prompted the same authors to recommend reserving the procedure for patients with severe recurrent acute attacks and highly impaired quality of life (QoL).&#x000a0;&#x000a0;</p>
        <p>Some studies are looking for other alternatives. These are in different phases of clinical trials, and this CME chapter at present, only seeks to inform the readers of these potential and futuristic therapies:</p>
        <p>
<bold>Potential/Experimental Therapies For AIP</bold>
</p>
        <p><bold>Enzyme Replacement Therapy [ERT]</bold> - Based on the experience of administering doses of recombinant human HMBS/PBGD (rhPBGD) protein in a mouse model of AIP that reduced plasma PBG accumulation during an acute attack induced after phenobarbital challenge,&#x000a0;in 2002 the European Medicines Agency (EMA) granted recombinant human HMBS/PBGD an orphan designation (EU/3/ 02/103). Researchers conducted clinical trials in healthy subjects, asymptomatic HMBS-deficient subjects with increased porphyrin precursor excretion, and AIP patients with repeated attacks.<xref ref-type="bibr" rid="article-27443.r28">[28]</xref><xref ref-type="bibr" rid="article-27443.r29">[29]</xref> Although the enzyme was able to detoxify PBG metabolites, the treatment approach limitations included its short half-life in circulation and the lack of liver targeting.&#x000a0;</p>
        <p><bold>Liver Gene Therapy</bold> - Clinical trials using two strategies, HMBS-gene therapy and interference RNA for ALAS1 gene inhibition,&#x000a0;are being conducted&#x000a0;in patients with AIP. The two strategies include&#x000a0; - the delivery of the HMBS gene to the hepatocytes using a viral vector. The other option is a small interfering RNA (siRNA) directed against aminolevulinic acid synthase, with the objective of reducing delta&#x000a0;ALA production. Both of them are still in the trial phase and await approval, pending larger trials that would hopefully provide consistent efficacy and safety.<xref ref-type="bibr" rid="article-27443.r20">[20]</xref><xref ref-type="bibr" rid="article-27443.r30">[30]</xref></p>
      </sec>
      <sec id="article-27443.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In an observational study of acute porphyrias, which included 90 patients with AIP, researchers found&#x000a0;that the diagnostic delay was a mean of 15 years.<xref ref-type="bibr" rid="article-27443.r31">[31]</xref> The predominance of the acute abdomen as the presenting symptom of an acute attack of AIP, patients often undergo appendectomies or cholecystectomies before the diagnosis of porphyria is suspected and/or confirmed.&#x000a0;</p>
        <p>Owing to the broad spectrum neuro-visceral clinical presentation of AIP, the list of differential diagnosis is long:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Other acute porphyrias -&#x000a0;Clinically, it is often difficult to differentiate from other acute porphyrias: HCP, VP, and Doss porphyria.</p>
          </list-item>
          <list-item>
            <p>Causes of acute abdomen - Peritonitis, appendicitis, acute cholecystitis,&#x000a0;acute gastritis, acute pancreatitis, intestinal occlusion, strangulated abdominal hernia, acute mesenteric ischemia, ileus, diverticulitis, esophagitis, endometriosis, gastric outlet obstruction, intussusception, pelvic inflammatory disease,&#x000a0;ovarian cysts, acute pyelonephritis, aortic dissection.</p>
          </list-item>
          <list-item>
            <p>Lead poisoning constitutes a substantial differential, and one must look for the presence of anemia and lead levels in the blood to confidently differentiate between the two conditions.<xref ref-type="bibr" rid="article-27443.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Causes associated with clinical features of autonomic neuropathy - Hypertensive crisis,&#x000a0;tachyarrhythmias,&#x000a0; adrenal crisis, familial Mediterranean fever, fibromyalgia</p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric simulators -&#x000a0;Acute psychotic attack, delirium, panic attack, Guillain-Barre syndrome.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27443.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis is good if acute intermittent porphyria is recognized early and treated at the time. The mortality has decreased through the past decades to 5% to 20% (on acute attacks) thanks to new methods of diagnosis and treatment. But if the disease is resistant to heme therapy and is recurrent, the only currently approved way to reduce mortality is with an orthotopic liver transplant.<xref ref-type="bibr" rid="article-27443.r17">[17]</xref><xref ref-type="bibr" rid="article-27443.r2">[2]</xref><xref ref-type="bibr" rid="article-27443.r1">[1]</xref></p>
        <p>With ongoing trials exploring the efficacy and safety of ERT and liver gene therapy, the prognosis of AIP is expected to become better very soon.</p>
        <p>Complications of acute intermittent porphyria (vide infra); arterial hypertension, chronic kidney disease, neurologic deficits, and risk of hepatocellular carcinoma must remain in check by ensuring close observation and review of the patient.</p>
      </sec>
      <sec id="article-27443.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="order">
          <list-item>
            <p>Systemic arterial hypertension and chronic kidney disease - Reports exist of the prevalence of up to 30% of these closely linked disorders in patients with AIP.<xref ref-type="bibr" rid="article-27443.r32">[32]</xref> End-stage renal disease (ESRD) is a life-threatening complication in AIP patients with chronic active disease.<xref ref-type="bibr" rid="article-27443.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Muscle denervation is another major pathologic complication.<xref ref-type="bibr" rid="article-27443.r6">[6]</xref> Some patients after acute attacks have residual deficits such as foot/wrist drop or wasting of the intrinsic muscles of hands.<xref ref-type="bibr" rid="article-27443.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma (HCC): This is the most deadly long-term complication of AIP.&#x000a0; Results of studies performed over the last 3 to 4 decades have shown a remarkably increased incidence of HCC in AIP patients compared with the general population.<xref ref-type="bibr" rid="article-27443.r34">[34]</xref> A Swedish study showed that the risk for HCC in AIP is increased 80 times after the age of 50 years.<xref ref-type="bibr" rid="article-27443.r11">[11]</xref><xref ref-type="bibr" rid="article-27443.r35">[35]</xref> It is worthwhile to know that AIP-associated HCC is typically free from the usual preceding comorbidities such as Hepatitis B or C infection.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27443.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>AIP is a rare autosomal dominant condition that&#x000a0;runs a chronic course with recurrent acute episodes of neurovisceral symptoms.&#x000a0;Trials are giving hope to find a definitive cure to this life -long disease. Once the diagnosis of AIP or some other acute hepatic porphyria is confirmed, patients should be thoroughly counseled and provided with the list of trigger factors (that can precipitate an attack) for avoidance, especially drugs that are safe and unsafe. They should know that treatment is only available for acute attacks and that the best way to remain asymptomatic is by preventing precipitants. If they have abdominal pain should go immediately to the emergency department. They should receive education on prognosis and complications and are strongly encouraged to obtain genetic testing done for their offspring.</p>
      </sec>
      <sec id="article-27443.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians should suspect acute intermittent porphyria should in patients with abdominal pain, and symptoms or signs suggestive of neuropsychiatric morbidity. A patient with a purely medical ailment often ends up with the surgeons due to recurrent acute abdomen and may undergo unnecessary surgeries. Thus, the surgical team should be aware of this non-surgical cause of severe acute abdomen and maintain a high index of suspicion in a patient with recurrent attacks or one who presents with additional neuropsychiatric symptoms.</p>
        <p>Interprofessional involvement of the primary care physician, nurse practitioner, metabolic/genetic disease expert, hematologist, biochemist, pharmacist, nursing, and the surgeon is essential to diagnose the disease early to limit the long-term complications of the patient. Lastly, the involvement of clinical geneticists for genetic counseling regarding the conception of a child by a patient with AIP is paramount to discuss the risk of acquisition, prenatal testing, and other aspects of prevention and/or early identification of AIP carrier state in the offspring. Nursing will be responsible for heme therapy administration and should monitor therapy progress as well as any adverse reactions, and inform the clinician should there be an issue. Pharmacists should verify dosing, as well as perform medication review to scan both for drug interactions, as well as drugs that can precipitate porphyria attacks, reporting any concerns to the team physicians managing the case. Open communication and collaboration between interprofessional members of the team are essential if one wants to avoid the high morbidity of this disorder. [Level V]</p>
      </sec>
      <sec id="article-27443.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27443&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27443">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/acute-intermittent-porphyria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27443">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27443/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27443">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27443.s15">
        <title>References</title>
        <ref id="article-27443.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rudnick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cengia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Acute Hepatic Porphyrias: Review and Recent Progress.</article-title>
            <source>Hepatol Commun</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-206</page-range>
            <pub-id pub-id-type="pmid">30766957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pischik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kauppinen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An update of clinical management of acute intermittent porphyria.</article-title>
            <source>Appl Clin Genet</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>201</fpage>
            <page-range>201-14</page-range>
            <pub-id pub-id-type="pmid">26366103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontanellas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Berraondo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Emerging therapies for acute intermittent porphyria.</article-title>
            <source>Expert Rev Mol Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>02</day>
            <volume>18</volume>
            <fpage>e17</fpage>
            <pub-id pub-id-type="pmid">27804912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szlendak</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bykowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lipniacka</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria.</article-title>
            <source>Adv Clin Exp Med</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>361</fpage>
            <page-range>361-8</page-range>
            <pub-id pub-id-type="pmid">27627571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roveri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nascimbeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ventura</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drugs and acute porphyrias: reasons for a hazardous relationship.</article-title>
            <source>Postgrad Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>126</volume>
            <issue>7</issue>
            <fpage>108</fpage>
            <page-range>108-20</page-range>
            <pub-id pub-id-type="pmid">25387219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramanujam</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.</article-title>
            <source>Curr Protoc Hum Genet</source>
            <year>2015</year>
            <month>Jul</month>
            <day>01</day>
            <volume>86</volume>
            <fpage>17.20.1</fpage>
            <page-range>17.20.1-17.20.26</page-range>
            <pub-id pub-id-type="pmid">26132003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cerbino</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Gerez</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Melito</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Parera</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Batlle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Acute intermittent porphyria in Argentina: an update.</article-title>
            <source>Biomed Res Int</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>946387</fpage>
            <pub-id pub-id-type="pmid">26075277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gouya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deybach</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Porphyrias.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Mar</month>
            <day>13</day>
            <volume>375</volume>
            <issue>9718</issue>
            <fpage>924</fpage>
            <page-range>924-37</page-range>
            <pub-id pub-id-type="pmid">20226990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Solis-Villa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hakenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balwani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doheny</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.</article-title>
            <source>Hum Mutat</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1215</fpage>
            <page-range>1215-1222</page-range>
            <pub-id pub-id-type="pmid">27539938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Storjord</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Landsem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fure</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ludviksen</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Goldbeck-Wood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karlsen</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Mollnes</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>W Nielsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brekke</surname>
                <given-names>OL</given-names>
              </name>
            </person-group>
            <article-title>Systemic inflammation in acute intermittent porphyria: a case-control study.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>187</volume>
            <issue>3</issue>
            <fpage>466</fpage>
            <page-range>466-479</page-range>
            <pub-id pub-id-type="pmid">27859020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sardh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barbaro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Intermittent Porphyria</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2005</year>
            <month>9</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">20301372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cederl&#x000f6;f</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Land&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden.</article-title>
            <source>Br J Psychiatry</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>207</volume>
            <issue>6</issue>
            <fpage>556</fpage>
            <page-range>556-7</page-range>
            <pub-id pub-id-type="pmid">26494868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Malley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bandmann</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Porphyria: often discussed but too often missed.</article-title>
            <source>Pract Neurol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>352</fpage>
            <page-range>352-358</page-range>
            <pub-id pub-id-type="pmid">29540448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pompilus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Querbes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strzok</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Penz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hungate</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marquis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations.</article-title>
            <source>Patient</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>527</fpage>
            <page-range>527-537</page-range>
            <pub-id pub-id-type="pmid">29915990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsden</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Urinary excretion of porphyrins, porphobilinogen and &#x003b4;-aminolaevulinic acid following an attack of acute intermittent porphyria.</article-title>
            <source>J Clin Pathol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-5</page-range>
            <pub-id pub-id-type="pmid">23908454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Biolcati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guida</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>E</given-names>
              </name>
              <collab>Gruppo Italiano Porfiria (GrIP)</collab>
            </person-group>
            <article-title>A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias.</article-title>
            <source>Eur J Intern Med</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>497</fpage>
            <page-range>497-505</page-range>
            <pub-id pub-id-type="pmid">24809927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmeltzer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Acute Porphyrias.</article-title>
            <source>J Emerg Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-12</page-range>
            <pub-id pub-id-type="pmid">26159905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Narang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thapar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Porphyrin and heme metabolism and the porphyrias.</article-title>
            <source>Compr Physiol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>365</fpage>
            <page-range>365-401</page-range>
            <pub-id pub-id-type="pmid">23720291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barman-Aks&#x000f6;zen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wegmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meienberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Minder</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komminoth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Minder</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Schneider-Yin</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.</article-title>
            <source>Scand J Clin Lab Invest</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>305</fpage>
            <page-range>305-313</page-range>
            <pub-id pub-id-type="pmid">31154864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Porphyria.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Aug</month>
            <day>31</day>
            <volume>377</volume>
            <issue>9</issue>
            <fpage>862</fpage>
            <page-range>862-872</page-range>
            <pub-id pub-id-type="pmid">28854095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aarsand</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.</article-title>
            <source>Clin Chem</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>650</fpage>
            <page-range>650-6</page-range>
            <pub-id pub-id-type="pmid">16595824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willandt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Langendonk</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Biermann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meersseman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>D'Heygere</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Verslype</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monbaliu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cassiman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series.</article-title>
            <source>JIMD Rep</source>
            <year>2016</year>
            <volume>25</volume>
            <fpage>77</fpage>
            <page-range>77-81</page-range>
            <pub-id pub-id-type="pmid">26093628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goetsch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bissell</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Instability of hematin used in the treatment of acute hepatic porphyria.</article-title>
            <source>N Engl J Med</source>
            <year>1986</year>
            <month>Jul</month>
            <day>24</day>
            <volume>315</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-8</page-range>
            <pub-id pub-id-type="pmid">3724815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doberer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haschemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andreas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zapf</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Clive</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jeitler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heinzl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wolzt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bilban</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>161</volume>
            <issue>8</issue>
            <fpage>1751</fpage>
            <page-range>1751-62</page-range>
            <pub-id pub-id-type="pmid">20718734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dover</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Fitzsimmons</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McColl</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria.</article-title>
            <source>Gastroenterology</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>500</fpage>
            <page-range>500-6</page-range>
            <pub-id pub-id-type="pmid">8335204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yasuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LU</given-names>
              </name>
              <name>
                <surname>Balwani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kadirvel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fiel</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clavero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arvelakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Sadagoparamanujam</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Florman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.</article-title>
            <source>Mol Med</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>487</fpage>
            <page-range>487-95</page-range>
            <pub-id pub-id-type="pmid">26062020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Gunson</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Bramhall</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Badminton</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Newsome</surname>
                <given-names>PN</given-names>
              </name>
              <collab>UK Liver Selection and Allocation Working Party</collab>
            </person-group>
            <article-title>Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis.</article-title>
            <source>Liver Transpl</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-200</page-range>
            <pub-id pub-id-type="pmid">21618697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johansson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fogh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.</article-title>
            <source>Mol Med</source>
            <year>2003</year>
            <season>Sep-Dec</season>
            <volume>9</volume>
            <issue>9-12</issue>
            <fpage>193</fpage>
            <page-range>193-9</page-range>
            <pub-id pub-id-type="pmid">15208740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rejkjaer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2007</year>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-49</page-range>
            <pub-id pub-id-type="pmid">17375984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Aseguinolaza</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute Intermittent Porphyria: Novel Etiologic and Pathogenic Therapies Based on RNA Transfer to the Liver.</article-title>
            <source>Hepatology</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>1061</fpage>
            <page-range>1061-1063</page-range>
            <pub-id pub-id-type="pmid">31026336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Maddukuri</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Bissell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bloomer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baillargeon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bossi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gandolfo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Light</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium.</article-title>
            <source>Am J Med</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>127</volume>
            <issue>12</issue>
            <fpage>1233</fpage>
            <page-range>1233-41</page-range>
            <pub-id pub-id-type="pmid">25016127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mami</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fran&#x000e7;ois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rabant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nochy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gouya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deybach</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Xu-Dubois</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Thervet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Puy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.</article-title>
            <source>Kidney Int</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>386</fpage>
            <page-range>386-95</page-range>
            <pub-id pub-id-type="pmid">25830761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Henrichson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.</article-title>
            <source>Cell Mol Biol (Noisy-le-grand)</source>
            <year>2009</year>
            <month>Feb</month>
            <day>16</day>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-71</page-range>
            <pub-id pub-id-type="pmid">19268004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up.</article-title>
            <source>J Clin Pathol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>976</fpage>
            <page-range>976-80</page-range>
            <pub-id pub-id-type="pmid">22851509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27443.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Porphyria.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>23</day>
            <volume>377</volume>
            <issue>21</issue>
            <fpage>2101</fpage>
            <pub-id pub-id-type="pmid">29166231</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
